. 2019 Oct 11;188(12):2097–2109. doi: 10.1093/aje/kwz232

Table 1.

Characteristics of Persons With Human Immunodeficiency Virus Using Antiretroviral Therapy, According to Key Population and Comparison Group, North American AIDS Cohort Collaboration on Research and Design, United States and Canada, 2004–2015

Characteristic	Black MSM (n = 4,569)		White MSM (n = 17,433)		Black Women (n = 6,696)		White Women (n = 2,880)		Hispanic Adults (n = 10,707)		Non-Hispanic Adults (n = 81,582)		IDU (n = 17,798)
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Age, years^a
20–39	2,366	52	5,708	33	2,843	42	1,141	40	4,418	41	23,443	29	2,973	17
40–49	1,497	33	7,029	40	2,432	36	1,100	38	3,511	33	29,284	36	7,234	41
50–59	576	13	3,690	21	1,179	18	502	17	2,094	20	21,133	26	6,515	37
≥60	130	3	1,006	6	242	4	137	5	684	6	7,722	9	1,076	6
Male sex^a	4,569	100	17,433	100	0	0	0	0	8,975	84	70,279	86	15,105	85
Race^a,b
White	0	0	17,433	100	0	0	2,880	100	0	0	38,979	48	5,630	32
Black	4,569	100	0	0	6,696	100	0	0	0	0	32,134	39	8,735	49
Hispanic	0	0	0	0	0	0	0	0	10,707	100	0	0	1,525	9
Other/unknown	0	0	0	0	0	0	0	0	0	0	10,469	13	1,908	11
HIV acquisition risk group^a
MSM	4,569	100	17,433	100	0	0	0	0	3,897	36	25,383	31	0	0
Heterosexual contact	0	0	0	0	3,586	54	1,534	53	1,961	18	9,856	12	0	0
IDU	0	0	0	0	1,067	16	827	29	1,525	14	16,273	20	17,798	100
Other/unknown	0	0	0	0	2,043	31	519	18	3,324	31	30,070	37	0	0
CD4 cell count, cells/mm³^c
2004–2007
Total	2,440		10,315		4,149		1,916		6,334		50,705		12,944
<200	779	32	2,014	20	1,150	28	439	23	1,586	25	12,952	26	3,820	30
200–349	563	23	2,501	24	1,037	25	447	23	1,463	23	12,264	24	3,211	25
350–500	438	18	2,103	20	752	18	378	20	1,071	17	9,615	19	2,260	17
≥500	591	24	3,348	32	1,083	26	597	31	1,513	24	13,832	27	2,932	23
Missing	69	3	349	3	127	3	55	3	701	11	2,042	4	721	6
2008–2011
Total	1,071		3,819		1,593		577		2,442		18,078		3,202
<200	289	27	688	18	444	28	130	23	598	24	4,580	25	927	29
200–349	259	24	962	25	419	26	142	25	590	24	4,737	26	915	29
350–500	254	24	906	24	314	20	121	21	520	21	3,919	22	635	20
≥500	252	24	1,168	31	374	23	173	30	556	23	4,339	24	617	19
Missing	17	2	95	2	42	3	11	2	178	7	503	3	108	3
2012–2015
Total	1,058		3,299		954		387		1,931		12,799		1,652
<200	174	16	408	12	167	18	80	21	284	15	2,252	18	309	19
200–349	164	16	495	15	185	19	67	17	311	16	2,176	17	329	20
350–500	244	23	631	19	200	21	63	16	385	20	2,547	20	327	20
≥500	445	42	1,664	50	384	40	168	43	769	40	5,411	42	614	37
Missing	31	3	101	3	18	2	9	2	182	9	413	3	73	4
Clinical AIDS diagnosis^d	1,087	24	3,873	22	1,721	26	704	24	2,308	22	15,798	19	3,617	20
Deaths while under follow-up	390	9	1,267	7	772	12	331	11	1,148	11	12,201	15	4,672	26
Loss to follow-up^e	1,173	26	4,669	27	1,305	19	630	22	2,717	25	13,493	17	1,877	11
Years of follow-up^f	4.3 (2.2, 7.9)		5.0 (2.5, 9.3)		5.4 (2.7, 9.8)		5.3 (2.6, 10.0)		5.0 (2.5, 9.6)		5.5 (2.7, 10.1)		6.3 (2.9, 11.0)

Abbreviations: AIDS, acquired immune deficiency syndrome; HIV, human immunodeficiency syndrome; IDU, injection drug use; MSM, men who have sex with men.

^a Year of birth, sex, race, and HIV acquisition risk group were measured at entry into the North American AIDS Cohort Collaboration on Research and Design.

^b Race was defined as black or white regardless Hispanic ethnicity.

^c CD4 count was measured as close to study entry as possible, within the window from before to 3 months after entry.

^d History of clinical AIDS diagnoses was defined by International Classification of Diseases, Ninth Revision, codes for AIDS-defining opportunistic infections and cancers.

^e Loss to follow-up was defined as a gap of >2 years without a CD4 or HIV RNA measurement.

^f Values are expressed as median (interquartile range).